Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

BackgroundBRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs).MethodsWe characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs an... Mehr ...

Verfasser: Silvestri, Valentina
Barrowdale, Daniel
Mulligan, Anna Marie
Neuhausen, Susan L
Fox, Stephen
Karlan, Beth Y
Mitchell, Gillian
James, Paul
Thull, Darcy L
Zorn, Kristin K
Carter, Natalie J
Nathanson, Katherine L
Domchek, Susan M
Rebbeck, Timothy R
Ramus, Susan J
Nussbaum, Robert L
Olopade, Olufunmilayo I
Rantala, Johanna
Yoon, Sook-Yee
Caligo, Maria A
Spugnesi, Laura
Bojesen, Anders
Pedersen, Inge Sokilde
Thomassen, Mads
Jensen, Uffe Birk
Toland, Amanda Ewart
Senter, Leigha
Andrulis, Irene L
Glendon, Gord
Hulick, Peter J
Imyanitov, Evgeny N
Greene, Mark H
Mai, Phuong L
Singer, Christian F
Rappaport-Fuerhauser, Christine
Kramer, Gero
Vijai, Joseph
Offit, Kenneth
Robson, Mark
Lincoln, Anne
Jacobs, Lauren
Machackova, Eva
Foretova, Lenka
Navratilova, Marie
Vasickova, Petra
Couch, Fergus J
Hallberg, Emily
Ruddy, Kathryn J
Sharma, Priyanka
Kim, Sung-Won
kConFab Investigators
Teixeira, Manuel R
Pinto, Pedro
Montagna, Marco
Matricardi, Laura
Arason, Adalgeir
Johannsson, Oskar Th
Barkardottir, Rosa B
Jakubowska, Anna
Lubinski, Jan
Izquierdo, Angel
Pujana, Miguel Angel
Balmaña, Judith
Diez, Orland
Ivady, Gabriella
Papp, Janos
Olah, Edith
Kwong, Ava
Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
Nevanlinna, Heli
Aittomäki, Kristiina
Perez Segura, Pedro
Caldes, Trinidad
Van Maerken, Tom
Poppe, Bruce
Claes, Kathleen BM
Isaacs, Claudine
Elan, Camille
Lasset, Christine
Stoppa-Lyonnet, Dominique
Barjhoux, Laure
Belotti, Muriel
Meindl, Alfons
Gehrig, Andrea
Sutter, Christian
Engel, Christoph
Niederacher, Dieter
Steinemann, Doris
Hahnen, Eric
Kast, Karin
Arnold, Norbert
Varon-Mateeva, Raymonda
Wand, Dorothea
Godwin, Andrew K
Evans, D Gareth
Frost, Debra
Perkins, Jo
Adlard, Julian
Izatt, Louise
Platte, Radka
Dokumenttyp: Artikel
Erscheinungsdatum: 2016
Reihe/Periodikum: Breast Cancer Research, vol 18, iss 1
Verlag/Hrsg.: eScholarship
University of California
Schlagwörter: Biomedical and Clinical Sciences / Clinical Sciences / Oncology and Carcinogenesis / Breast Cancer / Cancer / 2.1 Biological and endogenous factors / Aetiology / Adult / Aged / BRCA1 Protein / BRCA2 Protein / Breast Neoplasms / Male / Female / Genetic Predisposition to Disease / Humans / Middle Aged / Mutation / Neoplasm Staging / Polymorphism / Single Nucleotide / Male breast cancer / BRCA1/2 / Pathology / Histologic grade / Genotype-phenotype correlations / kConFab Investigators / Hereditary Breast and Ovarian Cancer Research Group Netherlands / EMBRACE / Oncology & Carcinogenesis
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-27180723
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://escholarship.org/uc/item/63r387vc

BackgroundBRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs).MethodsWe characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database.ResultsAmong BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10(-5)) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor-positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15-21.80] and progesterone receptor-positive (OR 5.04; 95 % CI 3.17-8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10(-12)).ConclusionsOn the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.